Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu
Trial record 29 of 53 for:    LENALIDOMIDE AND Leukemia AND Acute Myeloid Leukemia

Lenalidomide Plus Chemotherapy for AML

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01681537
Recruitment Status : Completed
First Posted : September 10, 2012
Last Update Posted : March 17, 2016
Information provided by (Responsible Party):
Karen Ballen, Massachusetts General Hospital

Brief Summary:

This research study is a Phase I clinical trial. Phase I clinical trials test the safety of an investigational combination of drugs. Phase I studies also try to define the appropriate dose of the investigational combination of drugs to use for further studies. "Investigational" means that the combination of drugs is still being studied and that research doctors are trying to find out more about it. It also means that the FDA has not approved this combination of drugs for AML. As part of this research study, you will take lenalidomide in combination with MEC. MEC are FDA approved chemotherapy drugs that are commonly used in the treatment of AML. Lenalidomide is approved by the FDA for patients with multiple myeloma, and some patients with myelodysplasia. Lenalidomide is considered investigational in this research study because it is not approved by the FDA for patients with AML.

Lenalidomide is a drug that affects the immune system, called an immunomodulatory drug or IMID. This drug is successful in the treatment of patients with multiple myeloma and some patients with myelodysplasia, a pre-leukemic condition. Other research studies suggest that lenalidomide may also be effective in patients with AML. Since we know that many patients who receive MEC chemotherapy alone do not have a prolonged remission (time free from leukemia), we are studying the addition of lenalidomide to MEC.

In this research study, we are looking for the highest dose of lenalidomide that can be given safely with MEC.

Condition or disease Intervention/treatment Phase
Acute Myelogenous Leukemia Drug: Lenalidomide Drug: Mitoxantrone Drug: Etoposide Drug: Cytarabine Phase 1

Detailed Description:

After undergoing screening procedures to confirm that you are eligible to participate in the research study you will be admitted to the hospital. You will likely receive the majority of treatment on an inpatient basis. You will remain in the hospital for at least Days 4-8 and will be discharged at the discretion of your study doctor. It is likely that you will be hospitalized for several weeks due to the risk of infection after chemotherapy.

Since we are looking for the highest dose of the study drug that can be administered safely without severe or unmanageable side effects in participants that have relapsed or refractory AML, not everyone who participates in this research study will receive the same dose of the study drug. The dose you get will depend on the number of participants who have been enrolled in the study before you and how well they have tolerated their doses.

If you take part in this study you will be given a study drug-dosing calendar. There is only one cycle of treatment, which will be 28 days long. On Days 1 to 14 you will receive the lenalidomide orally. On Days 4-8 you will receive MEC chemotherapy: mitoxantrone by IV (intravenously, into your vein) over 30 minutes, etoposide by IV over one hour, and cytarabine by IV over one hour.

While on this study you will undergo a daily clinical exam for the first 14 days and then at least twice a week until your blood counts recover from treatment. A clinical exam consists of a physical exam, questions about your general health and specific questions about any problems that you might be having and any medications you may be taking. You will also undergo blood tests to assess your disease status and determine organ function level. This will happen daily for the first 14 days and then at least once a week (but up to 3 times per week) until your blood counts recover from treatment. Additionally a bone marrow aspirate/biopsy will be completed at the time of blood cell count recovery (usually between days 20 and 45) and as clinically indicated.

We would like to keep track of your medical condition for up to two years after your final dose of study drug. We would like to do this by getting in touch with you every 6 months to see how you are doing. Keeping in touch with you and checking your condition helps us look at the long-term effects fo the research study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 36 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Study of Lenalidomide Plus Chemotherapy With Mitoxantrone, Etoposide, and Cytarabine for the Reinduction of Patients With Acute Myelogenous Leukemia
Study Start Date : September 2012
Actual Primary Completion Date : September 2015
Actual Study Completion Date : December 2015

Arm Intervention/treatment
Experimental: Treatment Arm
Lenalidomide and re-induction chemotherapy
Drug: Lenalidomide
Drug: Mitoxantrone
Drug: Etoposide
Drug: Cytarabine

Primary Outcome Measures :
  1. Safety of lenalidomide plus conventional chemotherapy for relapsed AML [ Time Frame: 2 years ]
    Evaluation of the safety of lenalidomide in combination with conventional chemotherapy for relapsed acute myelogenous leukemia. Dose limiting toxicity is defined as a Grade IV rash or delayed neutrophil or platelet recovery beyond Day 45 after start of chemotherapy in the absence of disease

Secondary Outcome Measures :
  1. Days to neutrophil recovery [ Time Frame: 2 years ]
    Evaluation of neutrophil recovery (the first 3 days of ANC>500)

  2. Complete Remission Rate [ Time Frame: 2 years ]
    Evaluation of the complete remission rate and the complete remission rate without platelet recovery

  3. Treatment-related mortality [ Time Frame: 2 years ]
    Evaluation of the treatment-related mortality, the number of non-relapse related deaths in the first 45 days of starting treatment

  4. Transfusion Support [ Time Frame: 2 years ]
    Evaluation of transfusion support, the number of red blood cell and platelet transfusions needed in the first 45 days of treatment

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Primary refractory disease following at least one cycle of induction therapy or first relapse or higher
  • Must be registered into RevAssist program
  • Able and willing to adhere to study schedule and other protocol requirements

Exclusion Criteria:

  • Pregnant or breastfeeding
  • Known hypersensitivity to thalidomide or lenalidomide
  • Known seropositive for HIV
  • Have had myocardial infarction within 6 months of enrollment or NYHA Class III or IV heart failure
  • Other serious medical conditions or psychiatric conditions
  • Major surgery within 28 days prior to treatment
  • Received investigational agent or cytotoxic chemotherapy (except hydroxyurea) within 2 weeks of study
  • Acute promyelocytic leukemia

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01681537

Layout table for location information
United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02115
Sponsors and Collaborators
Massachusetts General Hospital
Layout table for investigator information
Principal Investigator: Karen Ballen, MD Massachusetts General Hospital

Layout table for additonal information
Responsible Party: Karen Ballen, Principal Investigator, Massachusetts General Hospital Identifier: NCT01681537    
Other Study ID Numbers: 12-202
First Posted: September 10, 2012    Key Record Dates
Last Update Posted: March 17, 2016
Last Verified: March 2016
Keywords provided by Karen Ballen, Massachusetts General Hospital:
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Neoplasms by Histologic Type
Etoposide phosphate
Immunologic Factors
Physiological Effects of Drugs
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Growth Inhibitors
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antimetabolites, Antineoplastic
Antiviral Agents
Anti-Infective Agents
Immunosuppressive Agents
Sensory System Agents
Peripheral Nervous System Agents